Yahoo
NasdaqCM - Delayed Quote USD

Daxor Corporation (DXR)

9.20 +0.28 (+3.14%)
At close: October 30 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for DXR
Chart does not reflect overnight price.
  • Previous Close 8.92
  • Open 8.86
  • Bid 8.65 x 100
  • Ask 9.20 x 500
  • Day's Range 8.40 - 9.20
  • 52 Week Range 8.40 - 14.76
  • Volume 27,883
  • Avg. Volume 19,982
  • Market Cap (intraday) 53.712M
  • Beta (5Y Monthly) 0.35
  • PE Ratio (TTM) 8.36
  • EPS (TTM) 1.10
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date Jan 5, 2018
  • 1y Target Est 20.00

Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.

www.daxor.com

--

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

DXR
37.63%
S&P 500 (^GSPC)
10.73%

1-Year Return

DXR
31.19%
S&P 500 (^GSPC)
11.11%

3-Year Return

DXR
17.65%
S&P 500 (^GSPC)
81.91%

5-Year Return

DXR
14.89%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY19
Revenue 100k
Earnings 220k
Profit Margin 220.00%

Q2

FY07

Q3

FY07

Q1

FY19

Q2

FY19

0
100K
200K
300K
400K
500K
0.0%
50.0%
100.0%
150.0%
200.0%

Analyst Insights

View More

Analyst Price Targets

18.00
20.00 Average
9.20 Current
22.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 3/17/2025
Analyst Ascendiant Capital
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 24.75 -> 25

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    19,861.41%

  • Return on Assets (ttm)

    -2.63%

  • Return on Equity (ttm)

    14.24%

  • Revenue (ttm)

    31.36k

  • Net Income Avi to Common (ttm)

    6.23M

  • Diluted EPS (ttm)

    1.10

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    333.87k

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: